Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyEpirizole
Identification
- Name
- Epirizole
- Accession Number
- DB08991
- Type
- Small Molecule
- Groups
- Approved
- Description
Epirizole is a nonsteroidal anti-inflammatory drug (NSAID).
- Structure
Structure for DB08991 (Epirizole)
- Synonyms
- 4-methoxy-2-(5-methoxy-3-methylpyrazol-1-yl)-6-methylpyrimidine
- Epirizole
- Mebron
- Methopyrimazole
- Polihexanid
- External IDs
- DA 398 / DA-398 / Knoll 533
- Product Ingredients
Ingredient UNII CAS InChI Key Epirizole hydrochloride 138HY1BQ0T Not Available YJVOCLSBUGKSCI-UHFFFAOYSA-N - International/Other Brands
- Karmarte (Toho) / Mebron (Daiichi Sankyo)
- Categories
- UNII
- 3B46O2FH8I
- CAS number
- 18694-40-1
- Weight
- Average: 234.2545
Monoisotopic: 234.111675712 - Chemical Formula
- C11H14N4O2
- InChI Key
- RHAXSHUQNIEUEY-UHFFFAOYSA-N
- InChI
- InChI=1S/C11H14N4O2/c1-7-5-9(16-3)13-11(12-7)15-10(17-4)6-8(2)14-15/h5-6H,1-4H3
- IUPAC Name
- 4-methoxy-2-(5-methoxy-3-methyl-1H-pyrazol-1-yl)-6-methylpyrimidine
- SMILES
- COC1=CC(C)=NN1C1=NC(C)=CC(OC)=N1
Pharmacology
- Indication
- Not Available
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (4R)-limonene The risk or severity of adverse effects can be increased when (4R)-limonene is combined with Epirizole. Investigational 16-Bromoepiandrosterone The risk or severity of adverse effects can be increased when Epirizole is combined with 16-Bromoepiandrosterone. Investigational 19-norandrostenedione The risk or severity of adverse effects can be increased when Epirizole is combined with 19-norandrostenedione. Experimental, Illicit 5-androstenedione The risk or severity of adverse effects can be increased when Epirizole is combined with 5-androstenedione. Experimental, Illicit Abciximab Epirizole may increase the anticoagulant activities of Abciximab. Approved Acebutolol Epirizole may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Aceclofenac The risk or severity of adverse effects can be increased when Epirizole is combined with Aceclofenac. Approved, Investigational Acemetacin The risk or severity of adverse effects can be increased when Epirizole is combined with Acemetacin. Approved, Experimental, Investigational Acenocoumarol Epirizole may increase the anticoagulant activities of Acenocoumarol. Approved, Investigational Acetylsalicylic acid The risk or severity of adverse effects can be increased when Epirizole is combined with Acetylsalicylic acid. Approved, Vet Approved Adapalene The risk or severity of adverse effects can be increased when Adapalene is combined with Epirizole. Approved Alclofenac The risk or severity of adverse effects can be increased when Epirizole is combined with Alclofenac. Approved, Withdrawn Alclometasone The risk or severity of adverse effects can be increased when Epirizole is combined with Alclometasone. Approved Aldosterone The risk or severity of adverse effects can be increased when Epirizole is combined with Aldosterone. Experimental, Investigational Alendronic acid The risk or severity of adverse effects can be increased when Epirizole is combined with Alendronic acid. Approved Aliskiren Epirizole may decrease the antihypertensive activities of Aliskiren. Approved, Investigational Alminoprofen The risk or severity of adverse effects can be increased when Epirizole is combined with Alminoprofen. Experimental Alprenolol Epirizole may decrease the antihypertensive activities of Alprenolol. Approved, Withdrawn Alprostadil The therapeutic efficacy of Alprostadil can be decreased when used in combination with Epirizole. Approved, Investigational Amcinonide The risk or severity of adverse effects can be increased when Epirizole is combined with Amcinonide. Approved Amikacin The risk or severity of nephrotoxicity can be increased when Epirizole is combined with Amikacin. Approved, Investigational, Vet Approved Amiloride Epirizole may decrease the antihypertensive activities of Amiloride. Approved Aminosalicylic Acid The risk or severity of adverse effects can be increased when Epirizole is combined with Aminosalicylic Acid. Approved Amlodipine The therapeutic efficacy of Amlodipine can be decreased when used in combination with Epirizole. Approved Ancrod Epirizole may increase the anticoagulant activities of Ancrod. Approved, Investigational Andrographolide The risk or severity of adverse effects can be increased when Andrographolide is combined with Epirizole. Investigational Androstenedione The risk or severity of adverse effects can be increased when Epirizole is combined with Androstenedione. Experimental, Illicit Anecortave The risk or severity of adverse effects can be increased when Epirizole is combined with Anecortave. Investigational anecortave acetate The risk or severity of adverse effects can be increased when Epirizole is combined with anecortave acetate. Investigational Anisodamine The risk or severity of adverse effects can be increased when Epirizole is combined with Anisodamine. Investigational Antipyrine The risk or severity of adverse effects can be increased when Epirizole is combined with Antipyrine. Approved, Investigational Antithrombin III human Epirizole may increase the anticoagulant activities of Antithrombin III human. Approved Antrafenine The risk or severity of adverse effects can be increased when Epirizole is combined with Antrafenine. Approved Apixaban Epirizole may increase the anticoagulant activities of Apixaban. Approved Apocynin The risk or severity of adverse effects can be increased when Epirizole is combined with Apocynin. Investigational Apramycin Epirizole may decrease the excretion rate of Apramycin which could result in a higher serum level. Experimental, Vet Approved Apremilast The risk or severity of adverse effects can be increased when Apremilast is combined with Epirizole. Approved, Investigational Arbekacin Epirizole may decrease the excretion rate of Arbekacin which could result in a higher serum level. Approved, Investigational Ardeparin Epirizole may increase the anticoagulant activities of Ardeparin. Approved, Investigational, Withdrawn Argatroban Epirizole may increase the anticoagulant activities of Argatroban. Approved, Investigational Arotinolol Epirizole may decrease the antihypertensive activities of Arotinolol. Investigational Asenapine Epirizole may decrease the antihypertensive activities of Asenapine. Approved Atamestane The risk or severity of adverse effects can be increased when Epirizole is combined with Atamestane. Investigational Atenolol Epirizole may decrease the antihypertensive activities of Atenolol. Approved Azapropazone The risk or severity of adverse effects can be increased when Azapropazone is combined with Epirizole. Withdrawn Azelastine The risk or severity of adverse effects can be increased when Azelastine is combined with Epirizole. Approved Azficel-T The risk or severity of adverse effects can be increased when Epirizole is combined with Azficel-T. Approved, Investigational Azilsartan medoxomil The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Epirizole. Approved, Investigational Azosemide The therapeutic efficacy of Azosemide can be decreased when used in combination with Epirizole. Investigational Bacitracin The risk or severity of nephrotoxicity can be increased when Epirizole is combined with Bacitracin. Approved, Vet Approved Balsalazide The risk or severity of adverse effects can be increased when Epirizole is combined with Balsalazide. Approved, Investigational Becaplermin Epirizole may increase the anticoagulant activities of Becaplermin. Approved, Investigational Beclomethasone dipropionate The risk or severity of gastrointestinal irritation can be increased when Beclomethasone dipropionate is combined with Epirizole. Approved, Investigational Befunolol Epirizole may decrease the antihypertensive activities of Befunolol. Experimental Bekanamycin Epirizole may decrease the excretion rate of Bekanamycin which could result in a higher serum level. Experimental Benazepril The risk or severity of adverse effects can be increased when Epirizole is combined with Benazepril. Approved, Investigational Bendazac The risk or severity of adverse effects can be increased when Epirizole is combined with Bendazac. Experimental Bendroflumethiazide The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Epirizole. Approved Benorilate The risk or severity of adverse effects can be increased when Epirizole is combined with Benorilate. Experimental Benoxaprofen The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Epirizole. Withdrawn Benzthiazide The therapeutic efficacy of Benzthiazide can be decreased when used in combination with Epirizole. Approved Benzydamine The risk or severity of adverse effects can be increased when Epirizole is combined with Benzydamine. Approved Bepridil The therapeutic efficacy of Bepridil can be decreased when used in combination with Epirizole. Approved, Withdrawn Beraprost The therapeutic efficacy of Beraprost can be decreased when used in combination with Epirizole. Investigational Betamethasone The risk or severity of adverse effects can be increased when Epirizole is combined with Betamethasone. Approved, Vet Approved Betaxolol Epirizole may decrease the antihypertensive activities of Betaxolol. Approved, Investigational Betrixaban The risk or severity of bleeding can be increased when Betrixaban is combined with Epirizole. Approved, Investigational Bevantolol Epirizole may decrease the antihypertensive activities of Bevantolol. Approved Bevonium The risk or severity of adverse effects can be increased when Epirizole is combined with Bevonium. Experimental Bimatoprost The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Epirizole. Approved, Investigational Bisoprolol Epirizole may decrease the antihypertensive activities of Bisoprolol. Approved Bivalirudin Epirizole may increase the anticoagulant activities of Bivalirudin. Approved, Investigational Bopindolol Epirizole may decrease the antihypertensive activities of Bopindolol. Approved Bromfenac The risk or severity of adverse effects can be increased when Epirizole is combined with Bromfenac. Approved Bucillamine The risk or severity of adverse effects can be increased when Epirizole is combined with Bucillamine. Investigational Bucindolol Epirizole may decrease the antihypertensive activities of Bucindolol. Investigational Budesonide The risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Epirizole. Approved Bufexamac The risk or severity of adverse effects can be increased when Epirizole is combined with Bufexamac. Approved, Experimental Bufuralol Epirizole may decrease the antihypertensive activities of Bufuralol. Experimental, Investigational Bumadizone The risk or severity of adverse effects can be increased when Epirizole is combined with Bumadizone. Experimental Bumetanide The therapeutic efficacy of Bumetanide can be decreased when used in combination with Epirizole. Approved Bupranolol Epirizole may decrease the antihypertensive activities of Bupranolol. Approved Candesartan The risk or severity of adverse effects can be increased when Candesartan is combined with Epirizole. Experimental Candesartan cilexetil The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Epirizole. Approved Candoxatril The risk or severity of adverse effects can be increased when Epirizole is combined with Candoxatril. Experimental Capsaicin The risk or severity of adverse effects can be increased when Epirizole is combined with Capsaicin. Approved Captopril The risk or severity of adverse effects can be increased when Epirizole is combined with Captopril. Approved Carbaspirin calcium The risk or severity of adverse effects can be increased when Epirizole is combined with Carbaspirin calcium. Experimental, Investigational Carboprost Tromethamine The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Epirizole. Approved Carprofen The risk or severity of adverse effects can be increased when Epirizole is combined with Carprofen. Approved, Vet Approved, Withdrawn Carteolol Epirizole may decrease the antihypertensive activities of Carteolol. Approved Carvedilol Epirizole may decrease the antihypertensive activities of Carvedilol. Approved, Investigational Castanospermine The risk or severity of adverse effects can be increased when Castanospermine is combined with Epirizole. Experimental Celecoxib The risk or severity of adverse effects can be increased when Epirizole is combined with Celecoxib. Approved, Investigational Celiprolol Epirizole may decrease the antihypertensive activities of Celiprolol. Approved, Investigational Certoparin Epirizole may increase the anticoagulant activities of Certoparin. Approved, Investigational Chloroquine The risk or severity of adverse effects can be increased when Chloroquine is combined with Epirizole. Approved, Investigational, Vet Approved Chlorothiazide The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Epirizole. Approved, Vet Approved Chlorphenesin The risk or severity of adverse effects can be increased when Epirizole is combined with Chlorphenesin. Approved, Vet Approved, Withdrawn Chlorthalidone The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Epirizole. Approved Cholestyramine Cholestyramine can cause a decrease in the absorption of Epirizole resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Choline magnesium trisalicylate The risk or severity of adverse effects can be increased when Epirizole is combined with Choline magnesium trisalicylate. Approved Ciclesonide The risk or severity of adverse effects can be increased when Epirizole is combined with Ciclesonide. Approved, Investigational Cilazapril The risk or severity of adverse effects can be increased when Epirizole is combined with Cilazapril. Approved Cimicoxib The risk or severity of adverse effects can be increased when Epirizole is combined with Cimicoxib. Investigational Cinoxacin Epirizole may increase the neuroexcitatory activities of Cinoxacin. Approved, Investigational, Withdrawn Ciprofloxacin Epirizole may increase the neuroexcitatory activities of Ciprofloxacin. Approved, Investigational Cisplatin The risk or severity of adverse effects can be increased when Epirizole is combined with Cisplatin. Approved Clobetasol The risk or severity of adverse effects can be increased when Epirizole is combined with Clobetasol. Approved, Investigational Clobetasol propionate The risk or severity of adverse effects can be increased when Epirizole is combined with Clobetasol propionate. Approved Clobetasone The risk or severity of adverse effects can be increased when Epirizole is combined with Clobetasone. Approved Clocortolone The risk or severity of adverse effects can be increased when Epirizole is combined with Clocortolone. Approved Clodronic Acid The risk or severity of adverse effects can be increased when Epirizole is combined with Clodronic Acid. Approved, Investigational, Vet Approved Clonixin The risk or severity of adverse effects can be increased when Epirizole is combined with Clonixin. Approved Cloprostenol The therapeutic efficacy of Cloprostenol can be decreased when used in combination with Epirizole. Vet Approved Cloranolol Epirizole may decrease the antihypertensive activities of Cloranolol. Experimental Colesevelam Colesevelam can cause a decrease in the absorption of Epirizole resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Colestipol Colestipol can cause a decrease in the absorption of Epirizole resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Cortexolone 17α-propionate The risk or severity of adverse effects can be increased when Epirizole is combined with Cortexolone 17α-propionate. Investigational Corticosterone The risk or severity of adverse effects can be increased when Epirizole is combined with Corticosterone. Experimental Cortisone acetate The risk or severity of adverse effects can be increased when Epirizole is combined with Cortisone acetate. Approved, Investigational Curcumin The risk or severity of adverse effects can be increased when Epirizole is combined with Curcumin. Approved, Investigational Cyclopenthiazide The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Epirizole. Experimental Cyclosporine The risk or severity of renal failure and hypertension can be increased when Epirizole is combined with Cyclosporine. Approved, Investigational, Vet Approved Dabigatran etexilate Epirizole may increase the anticoagulant activities of Dabigatran etexilate. Approved Dalteparin Epirizole may increase the anticoagulant activities of Dalteparin. Approved Danaparoid Epirizole may increase the anticoagulant activities of Danaparoid. Approved, Withdrawn Darexaban Epirizole may increase the anticoagulant activities of Darexaban. Investigational Deferasirox The risk or severity of adverse effects can be increased when Epirizole is combined with Deferasirox. Approved, Investigational Deflazacort The risk or severity of adverse effects can be increased when Epirizole is combined with Deflazacort. Approved, Investigational Delapril The risk or severity of adverse effects can be increased when Epirizole is combined with Delapril. Investigational Desipramine Epirizole may decrease the antihypertensive activities of Desipramine. Approved, Investigational Desirudin Epirizole may increase the anticoagulant activities of Desirudin. Approved Desmopressin The risk or severity of adverse effects can be increased when Epirizole is combined with Desmopressin. Approved Desonide The risk or severity of adverse effects can be increased when Epirizole is combined with Desonide. Approved, Investigational Desoximetasone The risk or severity of adverse effects can be increased when Epirizole is combined with Desoximetasone. Approved Desoxycorticosterone acetate The risk or severity of adverse effects can be increased when Epirizole is combined with Desoxycorticosterone acetate. Approved Desoxycorticosterone Pivalate The risk or severity of adverse effects can be increased when Epirizole is combined with Desoxycorticosterone Pivalate. Experimental, Vet Approved Dexamethasone The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Epirizole. Approved, Investigational, Vet Approved Dexamethasone isonicotinate The risk or severity of adverse effects can be increased when Epirizole is combined with Dexamethasone isonicotinate. Vet Approved Dexibuprofen The risk or severity of adverse effects can be increased when Epirizole is combined with Dexibuprofen. Approved, Investigational Dexketoprofen The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Epirizole. Approved, Investigational Dexniguldipine The therapeutic efficacy of Dexniguldipine can be decreased when used in combination with Epirizole. Experimental Dextran Epirizole may increase the anticoagulant activities of Dextran. Approved, Investigational, Vet Approved Dibekacin Epirizole may decrease the excretion rate of Dibekacin which could result in a higher serum level. Experimental Dibotermin alfa The risk or severity of adverse effects can be increased when Epirizole is combined with Dibotermin alfa. Approved, Investigational Diclofenac The risk or severity of adverse effects can be increased when Diclofenac is combined with Epirizole. Approved, Vet Approved Dicoumarol Epirizole may increase the anticoagulant activities of Dicoumarol. Approved Difenpiramide The risk or severity of adverse effects can be increased when Epirizole is combined with Difenpiramide. Experimental Diflorasone The risk or severity of adverse effects can be increased when Epirizole is combined with Diflorasone. Approved Diflunisal The risk or severity of adverse effects can be increased when Epirizole is combined with Diflunisal. Approved, Investigational Difluocortolone The risk or severity of adverse effects can be increased when Epirizole is combined with Difluocortolone. Approved, Investigational, Withdrawn Difluprednate The risk or severity of adverse effects can be increased when Epirizole is combined with Difluprednate. Approved Digoxin The serum concentration of Digoxin can be increased when it is combined with Epirizole. Approved Dihydrostreptomycin Epirizole may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level. Investigational, Vet Approved Diltiazem The therapeutic efficacy of Diltiazem can be decreased when used in combination with Epirizole. Approved, Investigational Dinoprost The therapeutic efficacy of Dinoprost can be decreased when used in combination with Epirizole. Investigational Dinoprost Tromethamine The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Epirizole. Approved, Vet Approved Dinoprostone The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Epirizole. Approved Doxazosin The therapeutic efficacy of Doxazosin can be decreased when used in combination with Epirizole. Approved Drospirenone Epirizole may increase the hyperkalemic activities of Drospirenone. Approved Droxicam The risk or severity of adverse effects can be increased when Epirizole is combined with Droxicam. Withdrawn Duvelisib The risk or severity of adverse effects can be increased when Epirizole is combined with Duvelisib. Investigational E-6201 The risk or severity of adverse effects can be increased when Epirizole is combined with E-6201. Investigational Edetic Acid Epirizole may increase the anticoagulant activities of Edetic Acid. Approved, Vet Approved Edoxaban Epirizole may increase the anticoagulant activities of Edoxaban. Approved Efonidipine The therapeutic efficacy of Efonidipine can be decreased when used in combination with Epirizole. Approved, Investigational Enalapril The risk or severity of adverse effects can be increased when Epirizole is combined with Enalapril. Approved, Vet Approved Enalaprilat The risk or severity of adverse effects can be increased when Epirizole is combined with Enalaprilat. Approved Enoxacin Epirizole may increase the neuroexcitatory activities of Enoxacin. Approved, Investigational Enoxaparin Epirizole may increase the anticoagulant activities of Enoxaparin. Approved Enprostil The therapeutic efficacy of Enprostil can be decreased when used in combination with Epirizole. Experimental Epanolol Epirizole may decrease the antihypertensive activities of Epanolol. Experimental Epitizide The therapeutic efficacy of Epitizide can be decreased when used in combination with Epirizole. Experimental Eplerenone Epirizole may decrease the antihypertensive activities of Eplerenone. Approved Epoprostenol The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Epirizole. Approved Eprosartan The risk or severity of adverse effects can be increased when Eprosartan is combined with Epirizole. Approved Equilenin The risk or severity of adverse effects can be increased when Epirizole is combined with Equilenin. Experimental Equilin The risk or severity of adverse effects can be increased when Epirizole is combined with Equilin. Approved Esatenolol Epirizole may decrease the antihypertensive activities of Esatenolol. Experimental Esmolol Epirizole may decrease the antihypertensive activities of Esmolol. Approved Estrone The risk or severity of adverse effects can be increased when Epirizole is combined with Estrone. Approved Estrone sulfate The risk or severity of adverse effects can be increased when Epirizole is combined with Estrone sulfate. Approved Etacrynic acid The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Epirizole. Approved, Investigational Etanercept The risk or severity of adverse effects can be increased when Epirizole is combined with Etanercept. Approved, Investigational Ethenzamide The risk or severity of adverse effects can be increased when Epirizole is combined with Ethenzamide. Experimental Ethyl biscoumacetate Epirizole may increase the anticoagulant activities of Ethyl biscoumacetate. Withdrawn Etidronic acid The risk or severity of adverse effects can be increased when Epirizole is combined with Etidronic acid. Approved Etodolac The risk or severity of adverse effects can be increased when Epirizole is combined with Etodolac. Approved, Investigational, Vet Approved Etofenamate The risk or severity of adverse effects can be increased when Etofenamate is combined with Epirizole. Approved, Investigational Etoricoxib The risk or severity of adverse effects can be increased when Epirizole is combined with Etoricoxib. Approved, Investigational Evening primrose oil The risk or severity of adverse effects can be increased when Epirizole is combined with Evening primrose oil. Investigational, Nutraceutical Exisulind The risk or severity of adverse effects can be increased when Exisulind is combined with Epirizole. Investigational Felbinac The risk or severity of adverse effects can be increased when Felbinac is combined with Epirizole. Experimental Felodipine The therapeutic efficacy of Felodipine can be decreased when used in combination with Epirizole. Approved, Investigational Fenbufen The risk or severity of adverse effects can be increased when Fenbufen is combined with Epirizole. Approved Fenoprofen The risk or severity of adverse effects can be increased when Epirizole is combined with Fenoprofen. Approved Fenprostalene The therapeutic efficacy of Fenprostalene can be decreased when used in combination with Epirizole. Vet Approved Fentiazac The risk or severity of adverse effects can be increased when Epirizole is combined with Fentiazac. Experimental Feprazone The risk or severity of adverse effects can be increased when Epirizole is combined with Feprazone. Experimental Ferulic acid Epirizole may increase the anticoagulant activities of Ferulic acid. Experimental Fimasartan The risk or severity of adverse effects can be increased when Fimasartan is combined with Epirizole. Approved, Investigational Fleroxacin Epirizole may increase the neuroexcitatory activities of Fleroxacin. Approved Floctafenine The risk or severity of adverse effects can be increased when Floctafenine is combined with Epirizole. Approved, Withdrawn Fluasterone The risk or severity of adverse effects can be increased when Epirizole is combined with Fluasterone. Investigational Fludrocortisone The risk or severity of adverse effects can be increased when Epirizole is combined with Fludrocortisone. Approved, Investigational Fluindione Epirizole may increase the anticoagulant activities of Fluindione. Approved, Investigational Flumequine Epirizole may increase the neuroexcitatory activities of Flumequine. Withdrawn Flumethasone The risk or severity of adverse effects can be increased when Epirizole is combined with Flumethasone. Approved, Vet Approved Flunisolide The risk or severity of adverse effects can be increased when Epirizole is combined with Flunisolide. Approved, Investigational Flunixin The risk or severity of adverse effects can be increased when Epirizole is combined with Flunixin. Vet Approved Flunoxaprofen The risk or severity of adverse effects can be increased when Epirizole is combined with Flunoxaprofen. Experimental Fluocinolone Acetonide The risk or severity of adverse effects can be increased when Epirizole is combined with Fluocinolone Acetonide. Approved, Investigational, Vet Approved Fluocinonide The risk or severity of adverse effects can be increased when Epirizole is combined with Fluocinonide. Approved, Investigational Fluocortolone The risk or severity of adverse effects can be increased when Epirizole is combined with Fluocortolone. Approved, Withdrawn Fluorometholone The risk or severity of adverse effects can be increased when Epirizole is combined with Fluorometholone. Approved, Investigational Fluprednidene The risk or severity of adverse effects can be increased when Epirizole is combined with Fluprednidene. Approved, Withdrawn Fluprednisolone The risk or severity of adverse effects can be increased when Epirizole is combined with Fluprednisolone. Approved Fluprostenol The therapeutic efficacy of Fluprostenol can be decreased when used in combination with Epirizole. Vet Approved Flurandrenolide The risk or severity of adverse effects can be increased when Epirizole is combined with Flurandrenolide. Approved Flurbiprofen The risk or severity of adverse effects can be increased when Epirizole is combined with Flurbiprofen. Approved, Investigational Fluticasone The risk or severity of adverse effects can be increased when Epirizole is combined with Fluticasone. Approved, Experimental, Investigational Fluticasone furoate The risk or severity of adverse effects can be increased when Epirizole is combined with Fluticasone furoate. Approved Fluticasone propionate The risk or severity of gastrointestinal irritation can be increased when Fluticasone propionate is combined with Epirizole. Approved Folic Acid The therapeutic efficacy of Folic Acid can be decreased when used in combination with Epirizole. Approved, Nutraceutical, Vet Approved Fondaparinux Epirizole may increase the anticoagulant activities of Fondaparinux sodium. Approved, Investigational Forasartan The risk or severity of adverse effects can be increased when Forasartan is combined with Epirizole. Experimental Formestane The risk or severity of adverse effects can be increased when Epirizole is combined with Formestane. Approved, Investigational, Withdrawn Fosinopril The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Epirizole is combined with Fosinopril. Approved Framycetin Epirizole may decrease the excretion rate of Framycetin which could result in a higher serum level. Approved Furosemide The therapeutic efficacy of Furosemide can be decreased when used in combination with Epirizole. Approved, Vet Approved Gabexate Epirizole may increase the anticoagulant activities of Gabexate. Investigational Garenoxacin Epirizole may increase the neuroexcitatory activities of Garenoxacin. Investigational Gatifloxacin Epirizole may increase the neuroexcitatory activities of Gatifloxacin. Approved, Investigational Gemeprost The therapeutic efficacy of Gemeprost can be decreased when used in combination with Epirizole. Approved, Withdrawn Gemifloxacin Epirizole may increase the neuroexcitatory activities of Gemifloxacin. Approved, Investigational Geneticin Epirizole may decrease the excretion rate of Geneticin which could result in a higher serum level. Experimental Gentamicin Epirizole may decrease the excretion rate of Gentamicin which could result in a higher serum level. Approved, Vet Approved GENTAMICIN C1A Epirizole may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level. Experimental Ginseng The risk or severity of adverse effects can be increased when Epirizole is combined with Ginseng. Approved, Investigational, Nutraceutical Glipizide The protein binding of Glipizide can be decreased when combined with Epirizole. Approved, Investigational Glyburide The protein binding of Glyburide can be decreased when combined with Epirizole. Approved Grepafloxacin Epirizole may increase the neuroexcitatory activities of Grepafloxacin. Approved, Investigational, Withdrawn Guacetisal The risk or severity of adverse effects can be increased when Epirizole is combined with Guacetisal. Experimental Guanfacine The therapeutic efficacy of Guanfacine can be decreased when used in combination with Epirizole. Approved, Investigational Halcinonide The risk or severity of adverse effects can be increased when Epirizole is combined with Halcinonide. Approved, Investigational, Withdrawn Haloperidol The risk or severity of adverse effects can be increased when Epirizole is combined with Haloperidol. Approved HE3286 The risk or severity of adverse effects can be increased when Epirizole is combined with HE3286. Investigational Heparin Epirizole may increase the anticoagulant activities of Heparin. Approved, Investigational Higenamine The risk or severity of adverse effects can be increased when Epirizole is combined with Higenamine. Investigational Hydralazine Epirizole may decrease the antihypertensive activities of Hydralazine. Approved Hydrochlorothiazide The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Epirizole. Approved, Vet Approved Hydrocortisone The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Epirizole. Approved, Vet Approved Hydrocortisone acetate The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone acetate is combined with Epirizole. Approved, Vet Approved Hydrocortisone butyrate The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone butyrate is combined with Epirizole. Approved, Vet Approved Hydroflumethiazide The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Epirizole. Approved, Investigational Hygromycin B Epirizole may decrease the excretion rate of Hygromycin B which could result in a higher serum level. Vet Approved Ibandronate The risk or severity of gastrointestinal bleeding can be increased when Epirizole is combined with Ibandronate. Approved, Investigational Ibuprofen The risk or severity of adverse effects can be increased when Ibuprofen is combined with Epirizole. Approved Ibuproxam The risk or severity of adverse effects can be increased when Ibuproxam is combined with Epirizole. Withdrawn Icatibant The risk or severity of adverse effects can be increased when Icatibant is combined with Epirizole. Approved, Investigational Icosapent The risk or severity of adverse effects can be increased when Epirizole is combined with Icosapent. Approved, Nutraceutical Idraparinux Epirizole may increase the anticoagulant activities of Idraparinux. Investigational Iloprost The therapeutic efficacy of Iloprost can be decreased when used in combination with Epirizole. Approved, Investigational Imidapril The risk or severity of adverse effects can be increased when Epirizole is combined with Imidapril. Investigational Imidazole salicylate The risk or severity of adverse effects can be increased when Epirizole is combined with Imidazole salicylate. Experimental Indapamide The therapeutic efficacy of Indapamide can be decreased when used in combination with Epirizole. Approved Indenolol Epirizole may decrease the antihypertensive activities of Indenolol. Withdrawn Indobufen The risk or severity of adverse effects can be increased when Epirizole is combined with Indobufen. Investigational Indomethacin The risk or severity of adverse effects can be increased when Epirizole is combined with Indomethacin. Approved, Investigational Indoprofen The risk or severity of adverse effects can be increased when Indoprofen is combined with Epirizole. Withdrawn Irbesartan The risk or severity of adverse effects can be increased when Irbesartan is combined with Epirizole. Approved, Investigational Isepamicin Epirizole may decrease the excretion rate of Isepamicin which could result in a higher serum level. Experimental Isoxicam The risk or severity of adverse effects can be increased when Isoxicam is combined with Epirizole. Withdrawn Isradipine The therapeutic efficacy of Isradipine can be decreased when used in combination with Epirizole. Approved, Investigational Istaroxime The risk or severity of adverse effects can be increased when Epirizole is combined with Istaroxime. Investigational Kanamycin Epirizole may decrease the excretion rate of Kanamycin which could result in a higher serum level. Approved, Investigational, Vet Approved Kebuzone The risk or severity of adverse effects can be increased when Kebuzone is combined with Epirizole. Experimental Ketoprofen The risk or severity of adverse effects can be increased when Epirizole is combined with Ketoprofen. Approved, Vet Approved Ketorolac The risk or severity of adverse effects can be increased when Ketorolac is combined with Epirizole. Approved Labetalol Epirizole may decrease the antihypertensive activities of Labetalol. Approved Lacidipine The therapeutic efficacy of Lacidipine can be decreased when used in combination with Epirizole. Approved, Investigational Landiolol Epirizole may decrease the antihypertensive activities of Landiolol. Investigational Latanoprost The therapeutic efficacy of Latanoprost can be decreased when used in combination with Epirizole. Approved, Investigational Latanoprostene Bunod The therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Epirizole. Approved, Investigational Leflunomide The risk or severity of adverse effects can be increased when Leflunomide is combined with Epirizole. Approved, Investigational Lepirudin Epirizole may increase the anticoagulant activities of Lepirudin. Approved Lercanidipine The therapeutic efficacy of Lercanidipine can be decreased when used in combination with Epirizole. Approved, Investigational Letaxaban Epirizole may increase the anticoagulant activities of Letaxaban. Investigational Levobetaxolol Epirizole may decrease the antihypertensive activities of Levobetaxolol. Approved, Investigational Levobunolol Epirizole may decrease the antihypertensive activities of Levobunolol. Approved Levofloxacin Epirizole may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Limaprost The therapeutic efficacy of Limaprost can be decreased when used in combination with Epirizole. Approved, Investigational Lisinopril The risk or severity of adverse effects can be increased when Epirizole is combined with Lisinopril. Approved, Investigational Lisofylline The risk or severity of adverse effects can be increased when Epirizole is combined with Lisofylline. Investigational Lithium cation The serum concentration of Lithium can be increased when it is combined with Epirizole. Experimental Lomefloxacin Epirizole may increase the neuroexcitatory activities of Lomefloxacin. Approved, Investigational Lonazolac The risk or severity of adverse effects can be increased when Epirizole is combined with Lonazolac. Experimental Lornoxicam The risk or severity of adverse effects can be increased when Epirizole is combined with Lornoxicam. Approved, Investigational Losartan The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Epirizole. Approved Loteprednol The risk or severity of adverse effects can be increased when Epirizole is combined with Loteprednol. Approved Loxoprofen The risk or severity of adverse effects can be increased when Epirizole is combined with Loxoprofen. Approved, Investigational Lubiprostone The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Epirizole. Approved, Investigational Lumiracoxib The risk or severity of adverse effects can be increased when Epirizole is combined with Lumiracoxib. Approved, Investigational Luprostiol The therapeutic efficacy of Luprostiol can be decreased when used in combination with Epirizole. Vet Approved Magnesium salicylate The risk or severity of adverse effects can be increased when Epirizole is combined with Magnesium salicylate. Approved Manidipine The therapeutic efficacy of Manidipine can be decreased when used in combination with Epirizole. Approved, Investigational Masoprocol The risk or severity of adverse effects can be increased when Masoprocol is combined with Epirizole. Approved, Investigational ME-609 The risk or severity of adverse effects can be increased when Epirizole is combined with ME-609. Investigational Meclofenamic acid The risk or severity of adverse effects can be increased when Epirizole is combined with Meclofenamic acid. Approved, Vet Approved Medrysone The risk or severity of adverse effects can be increased when Epirizole is combined with Medrysone. Approved Mefenamic acid The risk or severity of adverse effects can be increased when Epirizole is combined with Mefenamic acid. Approved Melagatran Epirizole may increase the anticoagulant activities of Melagatran. Experimental Melengestrol The risk or severity of adverse effects can be increased when Epirizole is combined with Melengestrol. Vet Approved Meloxicam The risk or severity of adverse effects can be increased when Epirizole is combined with Meloxicam. Approved, Vet Approved Mepindolol Epirizole may decrease the antihypertensive activities of Mepindolol. Experimental Mesalazine The risk or severity of adverse effects can be increased when Epirizole is combined with Mesalazine. Approved Metamizole The risk or severity of adverse effects can be increased when Metamizole is combined with Epirizole. Approved, Investigational, Withdrawn Methotrexate The serum concentration of Methotrexate can be increased when it is combined with Epirizole. Approved Methyclothiazide The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Epirizole. Approved Methylprednisolone The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Epirizole. Approved, Vet Approved Metipranolol Epirizole may decrease the antihypertensive activities of Metipranolol. Approved Metolazone The therapeutic efficacy of Metolazone can be decreased when used in combination with Epirizole. Approved Metoprolol Epirizole may decrease the antihypertensive activities of Metoprolol. Approved, Investigational Mibefradil The therapeutic efficacy of Mibefradil can be decreased when used in combination with Epirizole. Investigational, Withdrawn Micronomicin Epirizole may decrease the excretion rate of Micronomicin which could result in a higher serum level. Experimental Mifamurtide The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Epirizole. Approved, Experimental Minoxidil The therapeutic efficacy of Minoxidil can be decreased when used in combination with Epirizole. Approved, Investigational Misoprostol The therapeutic efficacy of Misoprostol can be decreased when used in combination with Epirizole. Approved Mizoribine The risk or severity of adverse effects can be increased when Epirizole is combined with Mizoribine. Investigational Moexipril The risk or severity of adverse effects can be increased when Epirizole is combined with Moexipril. Approved Mofebutazone The risk or severity of adverse effects can be increased when Epirizole is combined with Mofebutazone. Experimental Mometasone The risk or severity of adverse effects can be increased when Epirizole is combined with Mometasone. Approved, Vet Approved Morniflumate The risk or severity of adverse effects can be increased when Morniflumate is combined with Epirizole. Approved Moxifloxacin Epirizole may increase the neuroexcitatory activities of Moxifloxacin. Approved, Investigational Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Epirizole. Approved, Investigational Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Epirizole. Approved Nabumetone The risk or severity of adverse effects can be increased when Epirizole is combined with Nabumetone. Approved Nadolol Epirizole may decrease the antihypertensive activities of Nadolol. Approved Nadroparin Epirizole may increase the anticoagulant activities of Nadroparin. Approved, Investigational Nafamostat Epirizole may increase the anticoagulant activities of Nafamostat. Approved, Investigational Naftifine The risk or severity of adverse effects can be increased when Naftifine is combined with Epirizole. Approved Naftopidil The therapeutic efficacy of Naftopidil can be decreased when used in combination with Epirizole. Investigational Nalidixic Acid Epirizole may increase the neuroexcitatory activities of Nalidixic Acid. Approved, Investigational Naproxen The risk or severity of adverse effects can be increased when Naproxen is combined with Epirizole. Approved, Vet Approved NCX 1022 The risk or severity of adverse effects can be increased when Epirizole is combined with NCX 1022. Investigational Neamine Epirizole may decrease the excretion rate of Neamine which could result in a higher serum level. Experimental Nebivolol Epirizole may decrease the antihypertensive activities of Nebivolol. Approved, Investigational Nemonoxacin Epirizole may increase the neuroexcitatory activities of Nemonoxacin. Investigational Neomycin The risk or severity of nephrotoxicity can be increased when Epirizole is combined with Neomycin. Approved, Vet Approved Nepafenac The risk or severity of adverse effects can be increased when Epirizole is combined with Nepafenac. Approved, Investigational Netilmicin Epirizole may decrease the excretion rate of Netilmicin which could result in a higher serum level. Approved, Investigational Nicardipine The therapeutic efficacy of Nicardipine can be decreased when used in combination with Epirizole. Approved, Investigational Nifenazone The risk or severity of adverse effects can be increased when Epirizole is combined with Nifenazone. Experimental Niflumic Acid The risk or severity of adverse effects can be increased when Epirizole is combined with Niflumic Acid. Approved Niguldipine The therapeutic efficacy of Niguldipine can be decreased when used in combination with Epirizole. Experimental Nilvadipine The therapeutic efficacy of Nilvadipine can be decreased when used in combination with Epirizole. Approved, Investigational Nimesulide The risk or severity of adverse effects can be increased when Nimesulide is combined with Epirizole. Approved, Investigational, Withdrawn Nimodipine The therapeutic efficacy of Nimodipine can be decreased when used in combination with Epirizole. Approved, Investigational Nisoldipine The therapeutic efficacy of Nisoldipine can be decreased when used in combination with Epirizole. Approved Nitrendipine The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Epirizole. Approved, Investigational Nitroaspirin The risk or severity of adverse effects can be increased when Epirizole is combined with Nitroaspirin. Investigational Norfloxacin Epirizole may increase the neuroexcitatory activities of Norfloxacin. Approved Ofloxacin Epirizole may increase the neuroexcitatory activities of Ofloxacin. Approved Oleoyl-estrone The risk or severity of adverse effects can be increased when Epirizole is combined with Oleoyl-estrone. Investigational Olmesartan The risk or severity of adverse effects can be increased when Olmesartan is combined with Epirizole. Approved, Investigational Olopatadine The risk or severity of adverse effects can be increased when Olopatadine is combined with Epirizole. Approved Olsalazine Epirizole may increase the nephrotoxic activities of Olsalazine. Approved Omacetaxine mepesuccinate The risk or severity of bleeding can be increased when Epirizole is combined with Omacetaxine mepesuccinate. Approved, Investigational Omapatrilat The risk or severity of adverse effects can be increased when Epirizole is combined with Omapatrilat. Investigational Orgotein The risk or severity of adverse effects can be increased when Epirizole is combined with Orgotein. Vet Approved Otamixaban Epirizole may increase the anticoagulant activities of Otamixaban. Investigational Oxaprozin The risk or severity of adverse effects can be increased when Epirizole is combined with Oxaprozin. Approved Oxolinic acid Epirizole may increase the neuroexcitatory activities of Oxolinic acid. Experimental Oxprenolol Epirizole may decrease the antihypertensive activities of Oxprenolol. Approved Oxyphenbutazone The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Epirizole. Approved, Withdrawn Palmidrol The risk or severity of adverse effects can be increased when Epirizole is combined with Palmidrol. Experimental, Nutraceutical Pamidronate The risk or severity of adverse effects can be increased when Epirizole is combined with Pamidronate. Approved Paramethasone The risk or severity of adverse effects can be increased when Epirizole is combined with Paramethasone. Approved Parecoxib The risk or severity of adverse effects can be increased when Epirizole is combined with Parecoxib. Approved Paromomycin The risk or severity of nephrotoxicity can be increased when Epirizole is combined with Paromomycin. Approved, Investigational Parthenolide The risk or severity of adverse effects can be increased when Epirizole is combined with Parthenolide. Approved, Investigational Pazufloxacin Epirizole may increase the neuroexcitatory activities of Pazufloxacin. Investigational Pefloxacin Epirizole may increase the neuroexcitatory activities of Pefloxacin. Approved Penbutolol Epirizole may decrease the antihypertensive activities of Penbutolol. Approved, Investigational Pentaerythritol Tetranitrate Epirizole may increase the anticoagulant activities of Pentaerythritol Tetranitrate. Approved Pentosan Polysulfate Epirizole may increase the anticoagulant activities of Pentosan Polysulfate. Approved Perindopril The risk or severity of adverse effects can be increased when Epirizole is combined with Perindopril. Approved Phenindione Epirizole may increase the anticoagulant activities of Phenindione. Approved, Investigational Phenprocoumon Epirizole may increase the anticoagulant activities of Phenprocoumon. Approved, Investigational Phenylbutazone The risk or severity of adverse effects can be increased when Epirizole is combined with Phenylbutazone. Approved, Vet Approved Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Epirizole. Approved, Investigational Pindolol Epirizole may decrease the antihypertensive activities of Pindolol. Approved, Investigational Pipemidic acid Epirizole may increase the neuroexcitatory activities of Pipemidic acid. Experimental Piretanide The therapeutic efficacy of Piretanide can be decreased when used in combination with Epirizole. Approved Pirfenidone The risk or severity of adverse effects can be increased when Pirfenidone is combined with Epirizole. Approved, Investigational Piromidic acid Epirizole may increase the neuroexcitatory activities of Piromidic acid. Experimental Piroxicam The risk or severity of adverse effects can be increased when Epirizole is combined with Piroxicam. Approved, Investigational Pirprofen The risk or severity of adverse effects can be increased when Epirizole is combined with Pirprofen. Experimental Pitolisant The risk or severity of adverse effects can be increased when Epirizole is combined with Pitolisant. Approved, Investigational Platelet Activating Factor Epirizole may decrease the antihypertensive activities of Platelet Activating Factor. Experimental Plazomicin Epirizole may decrease the excretion rate of Plazomicin which could result in a higher serum level. Approved, Investigational Polythiazide The therapeutic efficacy of Polythiazide can be decreased when used in combination with Epirizole. Approved Pomalidomide The risk or severity of adverse effects can be increased when Epirizole is combined with Pomalidomide. Approved Potassium Citrate Epirizole may increase the anticoagulant activities of Potassium Citrate. Approved, Investigational, Vet Approved Practolol Epirizole may decrease the antihypertensive activities of Practolol. Approved Pralatrexate The serum concentration of Pralatrexate can be increased when it is combined with Epirizole. Approved, Investigational Pranoprofen The risk or severity of adverse effects can be increased when Epirizole is combined with Pranoprofen. Experimental, Investigational Prasterone The risk or severity of adverse effects can be increased when Epirizole is combined with Prasterone. Approved, Investigational, Nutraceutical Prasterone sulfate The risk or severity of adverse effects can be increased when Epirizole is combined with Prasterone sulfate. Investigational Prednicarbate The risk or severity of adverse effects can be increased when Epirizole is combined with Prednicarbate. Approved, Investigational Prednisolone The risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Epirizole. Approved, Vet Approved Prednisone The risk or severity of adverse effects can be increased when Epirizole is combined with Prednisone. Approved, Vet Approved Pregnenolone The risk or severity of adverse effects can be increased when Epirizole is combined with Pregnenolone. Approved, Experimental, Investigational Probenecid The serum concentration of Epirizole can be increased when it is combined with Probenecid. Approved, Investigational Proglumetacin The risk or severity of adverse effects can be increased when Epirizole is combined with Proglumetacin. Experimental Propacetamol The risk or severity of adverse effects can be increased when Epirizole is combined with Propacetamol. Approved, Investigational Propafenone Epirizole may decrease the antihypertensive activities of Propafenone. Approved Propranolol Epirizole may decrease the antihypertensive activities of Propranolol. Approved, Investigational Propyphenazone The risk or severity of adverse effects can be increased when Epirizole is combined with Propyphenazone. Experimental Proquazone The risk or severity of adverse effects can be increased when Epirizole is combined with Proquazone. Experimental Prostaglandin B2 The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Epirizole. Experimental Prostaglandin G2 The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Epirizole. Experimental Prostalene The therapeutic efficacy of Prostalene can be decreased when used in combination with Epirizole. Vet Approved Protein C Epirizole may increase the anticoagulant activities of Protein C. Approved Protein S human Epirizole may increase the anticoagulant activities of Protein S human. Approved Protocatechualdehyde Epirizole may increase the anticoagulant activities of Protocatechualdehyde. Approved Prulifloxacin Epirizole may increase the neuroexcitatory activities of Prulifloxacin. Investigational PTC299 The risk or severity of adverse effects can be increased when PTC299 is combined with Epirizole. Investigational Puromycin Epirizole may decrease the excretion rate of Puromycin which could result in a higher serum level. Experimental Quinapril The risk or severity of adverse effects can be increased when Epirizole is combined with Quinapril. Approved, Investigational Quinethazone The therapeutic efficacy of Quinethazone can be decreased when used in combination with Epirizole. Approved Ramipril The risk or severity of adverse effects can be increased when Epirizole is combined with Ramipril. Approved Rescinnamine The risk or severity of adverse effects can be increased when Epirizole is combined with Rescinnamine. Approved Resveratrol The risk or severity of adverse effects can be increased when Epirizole is combined with Resveratrol. Approved, Experimental, Investigational Reviparin Epirizole may increase the anticoagulant activities of Reviparin. Approved, Investigational Ribostamycin Epirizole may decrease the excretion rate of Ribostamycin which could result in a higher serum level. Approved, Investigational Rimexolone The risk or severity of adverse effects can be increased when Epirizole is combined with Rimexolone. Approved Risedronate The risk or severity of adverse effects can be increased when Epirizole is combined with Risedronate. Approved, Investigational Rivaroxaban Epirizole may increase the anticoagulant activities of Rivaroxaban. Approved Rofecoxib The risk or severity of adverse effects can be increased when Epirizole is combined with Rofecoxib. Approved, Investigational, Withdrawn Rosoxacin Epirizole may increase the neuroexcitatory activities of Rosoxacin. Approved, Investigational Rufloxacin Epirizole may increase the neuroexcitatory activities of Rufloxacin. Experimental Sacubitril The risk or severity of adverse effects can be increased when Sacubitril is combined with Epirizole. Approved Salicylamide The risk or severity of adverse effects can be increased when Salicylamide is combined with Epirizole. Approved Salicylic acid The risk or severity of adverse effects can be increased when Salicylic acid is combined with Epirizole. Approved, Investigational, Vet Approved Salsalate The risk or severity of adverse effects can be increased when Epirizole is combined with Salsalate. Approved Saprisartan The risk or severity of adverse effects can be increased when Saprisartan is combined with Epirizole. Experimental Saralasin The risk or severity of adverse effects can be increased when Saralasin is combined with Epirizole. Investigational Sarilumab Sarilumab may increase the immunosuppressive activities of Epirizole. Approved, Investigational Seliciclib The risk or severity of adverse effects can be increased when Epirizole is combined with Seliciclib. Investigational Semapimod The risk or severity of adverse effects can be increased when Epirizole is combined with Semapimod. Investigational Seratrodast The risk or severity of adverse effects can be increased when Seratrodast is combined with Epirizole. Approved Serrapeptase The risk or severity of adverse effects can be increased when Epirizole is combined with Serrapeptase. Investigational Sisomicin Epirizole may decrease the excretion rate of Sisomicin which could result in a higher serum level. Investigational Sitafloxacin Epirizole may increase the neuroexcitatory activities of Sitafloxacin. Experimental, Investigational Sodium Citrate The risk or severity of bleeding and hemorrhage can be increased when Epirizole is combined with Sodium Citrate. Approved, Investigational Sodium phosphate, monobasic The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Epirizole. Approved Sotalol Epirizole may decrease the antihypertensive activities of Sotalol. Approved Sparfloxacin Epirizole may increase the neuroexcitatory activities of Sparfloxacin. Approved, Investigational Spirapril The risk or severity of adverse effects can be increased when Epirizole is combined with Spirapril. Approved Spironolactone The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Epirizole is combined with Spironolactone. Approved SRT501 The risk or severity of adverse effects can be increased when SRT501 is combined with Epirizole. Investigational Streptomycin Epirizole may decrease the excretion rate of Streptomycin which could result in a higher serum level. Approved, Vet Approved Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Epirizole. Approved Sulindac The risk or severity of adverse effects can be increased when Sulindac is combined with Epirizole. Approved, Investigational Sulodexide Epirizole may increase the anticoagulant activities of Sulodexide. Approved, Investigational Sulprostone The therapeutic efficacy of Sulprostone can be decreased when used in combination with Epirizole. Investigational Suprofen The risk or severity of adverse effects can be increased when Epirizole is combined with Suprofen. Approved, Withdrawn Suxibuzone The risk or severity of adverse effects can be increased when Epirizole is combined with Suxibuzone. Experimental Tacrolimus Epirizole may increase the nephrotoxic activities of Tacrolimus. Approved, Investigational Tafluprost The therapeutic efficacy of Tafluprost can be decreased when used in combination with Epirizole. Approved Talinolol Epirizole may decrease the antihypertensive activities of Talinolol. Investigational Talniflumate The risk or severity of adverse effects can be increased when Talniflumate is combined with Epirizole. Approved Tarenflurbil The risk or severity of adverse effects can be increased when Tarenflurbil is combined with Epirizole. Investigational Tasosartan The risk or severity of adverse effects can be increased when Tasosartan is combined with Epirizole. Approved Technetium Tc-99m etidronate The risk or severity of adverse effects can be increased when Epirizole is combined with Technetium Tc-99m etidronate. Approved Technetium Tc-99m medronate The risk or severity of adverse effects can be increased when Epirizole is combined with Technetium Tc-99m medronate. Approved Telmisartan The risk or severity of adverse effects can be increased when Telmisartan is combined with Epirizole. Approved, Investigational Temafloxacin Epirizole may increase the neuroexcitatory activities of Temafloxacin. Withdrawn Temocapril The risk or severity of adverse effects can be increased when Epirizole is combined with Temocapril. Experimental, Investigational Tenidap The risk or severity of adverse effects can be increased when Epirizole is combined with Tenidap. Experimental Tenofovir disoproxil The risk or severity of adverse effects can be increased when Epirizole is combined with Tenofovir disoproxil. Approved, Investigational Tenoxicam The risk or severity of adverse effects can be increased when Epirizole is combined with Tenoxicam. Approved Tepoxalin The risk or severity of adverse effects can be increased when Epirizole is combined with Tepoxalin. Vet Approved Terbutaline Epirizole may decrease the antihypertensive activities of Terbutaline. Approved Teriflunomide The risk or severity of adverse effects can be increased when Teriflunomide is combined with Epirizole. Approved Tertatolol Epirizole may decrease the antihypertensive activities of Tertatolol. Experimental Tetrahydropalmatine The therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Epirizole. Investigational Tiaprofenic acid The risk or severity of adverse effects can be increased when Epirizole is combined with Tiaprofenic acid. Approved Tiludronic acid The risk or severity of adverse effects can be increased when Epirizole is combined with Tiludronic acid. Approved, Investigational, Vet Approved Timolol Epirizole may decrease the antihypertensive activities of Timolol. Approved Tinoridine The risk or severity of adverse effects can be increased when Epirizole is combined with Tinoridine. Investigational Tixocortol The risk or severity of adverse effects can be increased when Epirizole is combined with Tixocortol. Approved, Withdrawn Tobramycin Epirizole may decrease the excretion rate of Tobramycin which could result in a higher serum level. Approved, Investigational Tolfenamic Acid The risk or severity of adverse effects can be increased when Epirizole is combined with Tolfenamic Acid. Approved, Investigational Tolmetin The risk or severity of adverse effects can be increased when Epirizole is combined with Tolmetin. Approved Torasemide The therapeutic efficacy of Torasemide can be decreased when used in combination with Epirizole. Approved Trandolapril The risk or severity of adverse effects can be increased when Epirizole is combined with Trandolapril. Approved Travoprost The therapeutic efficacy of Travoprost can be decreased when used in combination with Epirizole. Approved Treprostinil The risk or severity of adverse effects can be increased when Treprostinil is combined with Epirizole. Approved, Investigational Triamcinolone The risk or severity of adverse effects can be increased when Epirizole is combined with Triamcinolone. Approved, Vet Approved Triamterene Epirizole may decrease the antihypertensive activities of Triamterene. Approved Tribenoside The risk or severity of adverse effects can be increased when Epirizole is combined with Tribenoside. Experimental Trichlormethiazide The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Epirizole. Approved, Vet Approved Triptolide The risk or severity of adverse effects can be increased when Epirizole is combined with Triptolide. Investigational Trolamine salicylate The risk or severity of adverse effects can be increased when Epirizole is combined with Trolamine salicylate. Approved Trovafloxacin Epirizole may increase the neuroexcitatory activities of Trovafloxacin. Approved, Investigational, Withdrawn Troxerutin Epirizole may increase the anticoagulant activities of Troxerutin. Investigational Ulobetasol The risk or severity of adverse effects can be increased when Epirizole is combined with Ulobetasol. Approved Unoprostone The therapeutic efficacy of Unoprostone can be decreased when used in combination with Epirizole. Approved, Investigational Valdecoxib The risk or severity of adverse effects can be increased when Epirizole is combined with Valdecoxib. Approved, Investigational, Withdrawn Valsartan The risk or severity of adverse effects can be increased when Valsartan is combined with Epirizole. Approved, Investigational Vancomycin Epirizole may decrease the excretion rate of Vancomycin which could result in a higher serum level. Approved Warfarin Epirizole may increase the anticoagulant activities of Warfarin. Approved Ximelagatran Epirizole may increase the anticoagulant activities of Ximelagatran. Approved, Investigational, Withdrawn Zaltoprofen The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Epirizole. Approved, Investigational Zileuton The risk or severity of adverse effects can be increased when Zileuton is combined with Epirizole. Approved, Investigational, Withdrawn Zofenopril The risk or severity of adverse effects can be increased when Epirizole is combined with Zofenopril. Experimental Zoledronic acid The risk or severity of gastrointestinal bleeding can be increased when Epirizole is combined with Zoledronic acid. Approved Zomepirac The risk or severity of adverse effects can be increased when Zomepirac is combined with Epirizole. Withdrawn - Food Interactions
- Not Available
References
- Synthesis Reference
South African Patent Application 67/4936; January 19, 1968; assigned to Daiichi Seiyaku Company Limited, Japan.
- General References
- Not Available
- External Links
- KEGG Drug
- D01394
- PubChem Compound
- 3242
- PubChem Substance
- 310264952
- ChemSpider
- 3129
- ChEBI
- 31545
- ChEMBL
- CHEMBL1411693
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Epirizole
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 90-92 South African Patent Application 67/4936; January 19, 1968; assigned to Daiichi Seiyaku Company Limited, Japan. - Predicted Properties
Property Value Source Water Solubility 1.13 mg/mL ALOGPS logP 1.56 ALOGPS logP 1.45 ChemAxon logS -2.3 ALOGPS pKa (Strongest Basic) 2.25 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 5 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 62.06 Å2 ChemAxon Rotatable Bond Count 3 ChemAxon Refractivity 62.71 m3·mol-1 ChemAxon Polarizability 24.79 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-qTof , Positive LC-MS/MS Not Available MS/MS Spectrum - , positive LC-MS/MS splash10-000i-0390000000-9b005e40342ab7df46f0 MS/MS Spectrum - , positive LC-MS/MS splash10-00di-3930000000-1626dd87c849d820e5e4
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as alkyl aryl ethers. These are organic compounds containing the alkyl aryl ether functional group with the generic formula R-O-R' , where R is an alkyl group and R' is an aryl group.
- Kingdom
- Organic compounds
- Super Class
- Organic oxygen compounds
- Class
- Organooxygen compounds
- Sub Class
- Ethers
- Direct Parent
- Alkyl aryl ethers
- Alternative Parents
- Pyrimidines and pyrimidine derivatives / Pyrazoles / Heteroaromatic compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Hydrocarbon derivatives
- Substituents
- Alkyl aryl ether / Pyrimidine / Heteroaromatic compound / Pyrazole / Azole / Azacycle / Organoheterocyclic compound / Organic nitrogen compound / Organopnictogen compound / Hydrocarbon derivative
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
Drug created on June 10, 2014 17:13 / Updated on August 02, 2018 06:12